Table 1.
Clinical characteristics of enrolled adult patients with COVID-19
| All patients (n = 68) | ⩽60 years (n = 55) | >60 years (n = 13) | P value | |
|---|---|---|---|---|
| Age – years | 44.3 ± 16.4 | 37.7 ± 9.6 | 71.9 ± 7.8 | <0.001 |
| Gender (male/female) – no. (%) | 25/43 (36.8/63.2) | 17/38 (30.9/69.1) | 8/5 (61.5/38.5) | <0.05 |
| Medical staff – no. (%) | 41 (60.3) | 40 (72.7) | 1 (7.7) | <0.001 |
| Underlying disease – no. (%) | 14 (20.6) | 8 (14.5) | 6 (46.2) | <0.05 |
| Hypertension | 1 (1.5) | 0 (0.0) | 1 (7.7) | <0.05 |
| Coronary heart disease | 4 (5.9) | 2 (3.6) | 2 (15.4) | 0.11 |
| Diabetes mellitus | 3 (4.4) | 1 (1.8) | 2 (15.4) | <0.05 |
| Lacunar infarction | 2 (2.9) | 0 (0.0) | 2 (15.4) | <0.01 |
| Pulmonary tuberculosis | 4 (5.9) | 4 (7.3) | 0 (0.0) | 0.32 |
| Emphysema | 3 (4.4) | 1 (1.8) | 2 (15.4) | <0.05 |
| Asthma | 1 (1.5) | 1 (1.8) | 0 (0.0) | 0.62 |
| Myocarditis | 1 (1.5) | 0 (0.0) | 1 (7.7) | <0.05 |
| Medication history – no. (%) | ||||
| ACEI/ARB | 4 (5.9) | 2 (3.6) | 2 (15.4) | 0.11 |
| β-receptor blocker | 2 (2.9) | 0 (0.0) | 2 (15.4) | <0.01 |
| Calcium channel blocker | 1 (1.5) | 0 (0.0) | 1 (7.7) | <0.05 |
| Bayaspirin | 2 (2.9) | 0 (0.0) | 2 (15.4) | <0.01 |
| Statins | 2 (2.9) | 0 (0.0) | 2 (15.4) | <0.01 |
| Insulin | 1 (1.5) | 0 (0.0) | 1 (7.7) | <0.05 |
| Oral antidiabetic drugs | 3 (4.4) | 1 (1.8) | 2 (15.4) | <0.05 |
| Isolate-time – days | 13.8 ± 6.1 | 13.2 ± 5.8 | 16.4 ± 7.0 | 0.09 |
| Frequency of RNA detection – no. | 7.3 ± 3.5 | 6.9 ± 2.7 | 9.1 ± 5.7 | 0.45 |
| Frequency of positive RNA – no. | 0.8 ± 1.7 | 0.6 ± 1.1 | 1.8 ± 3.0 | 0.54 |
| Maximum time of RP – days | 7 | 7 | 5 | − |
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.
Plus–minus values are means ± s.d.